M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

Phase 2

Terminated

Conditions: Leukemia, Lymphoblastic
Leukemia

Interventions: Drug: CB-103
Drug: Venetoclax

First Posted Date: 2022-07-19

Last Posted Date: 2024-08-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT05464836

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma

Not Applicable

Active, not recruiting

Conditions: Lymphoma

Interventions: Other: Molecular Functional Portrait

First Posted Date: 2022-07-19

Last Posted Date: 2025-03-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 111

Registration Number: NCT05464823

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Implementation of Digital Vital Sign Monitoring to Decrease Sleep Interruption and Enhance Recovery in Phase II of the PROmoting Sleep, Patient Engagement and Recovery (PROSPER) Project

Phase 2

Terminated

Conditions: Sleep

Interventions: Device: ViSi Mobile device
Drug: Sleep enhancement intervention

First Posted Date: 2022-07-13

Last Posted Date: 2024-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 89

Registration Number: NCT05456360

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Other: Focal Cryoablation
Other: Standard of Care
Other: Quality-of-life Questionnaires

First Posted Date: 2022-07-12

Last Posted Date: 2025-04-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT05454488

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers

Not Applicable

Recruiting

Conditions: Cancer
Aging
Communication

Interventions: Behavioral: Geriatric Assessment

First Posted Date: 2022-06-29

Last Posted Date: 2025-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1500

Registration Number: NCT05436327

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

Phase 2

Recruiting

Conditions: Neuroleptics
Delirium
Epileptics

Interventions: Drug: Valproate
Drug: Haloperidol
Drug: Chlorpromazine
Drug: Placebo

First Posted Date: 2022-06-24

Last Posted Date: 2025-05-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT05431595

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Phase 1

Withdrawn

Conditions: Tumors
Ovarian Cancer
Breast Cancer
Lung Cancer
Pancreatic Cancer

Interventions: Drug: ZN-c3
Drug: Bevacizumab
Drug: Pembrolizumab

First Posted Date: 2022-06-24

Last Posted Date: 2023-06-15

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05431582

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

Phase 2

Recruiting

Conditions: T Cells
Colorectal Cancer
Lynch Syndrome

Interventions: Drug: Naproxen
Drug: Aspirin

First Posted Date: 2022-06-09

Last Posted Date: 2025-04-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT05411718

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Pilot Study Assessing the Effectiveness of Use of Guided Imagery for Treatment of Pain and Symptom Management in Women With Post-mastectomy Pain Syndrome

Not Applicable

Completed

Conditions: Symptom Management
Pain Syndrome
Pain

Interventions: Other: The Intervention Group
Other: The Control Group

First Posted Date: 2022-06-07

Last Posted Date: 2024-10-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT05408741

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

Recruiting

Conditions: Invasive Breast Carcinoma
Breast Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Radiation: Radiation Therapy

First Posted Date: 2022-06-06

Last Posted Date: 2025-02-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT05406232

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy